All In Biotech

Drug Trial Radar · NCT07814651

A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly

A Randomized, Parallel-group, Multicenter Phase II Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Long-acting Octreotide Injection in Patients With Acromegaly.

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Apr 16, 2024

Primary completion

Apr 9, 2026

Study completion Apr 23, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a phase II clinical trial to evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of octreotide long-acting injection in patients with acromegaly.

Conditions

  • Acromegaly

Interventions

  • SYHX2008Drug

    The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 12 weeks.

  • Sandostatin LARDrug

    The patients will accept Sandostatin LAR by intra-muscular administration.A treatment period of 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with an IGF-1 index ≤ 1.0Time frame: Weeks 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.